Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.

[1]  Y. Kinoshita,et al.  Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists , 2004, Alimentary pharmacology & therapeutics.

[2]  G. Barbara,et al.  Unsolved problems in the management of patients with gastro-oesophageal reflux disease. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  Y. Kinoshita,et al.  Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection , 2003, Journal of gastroenterology and hepatology.

[4]  Toshiharu Takashima,et al.  Comparative evaluation of urine-based and other minimally invasive methods for the diagnosis of Helicobacter pylori infection , 2002, Journal of Gastroenterology.

[5]  H. Iishi,et al.  Randomized comparative study of omeprazole and famotidine in reflux esophagitis , 2002, Journal of gastroenterology and hepatology.

[6]  S. Ishihara,et al.  Cardiovascular Risk Factors in Subjects with Helicobacter pylori Infection , 2002, Helicobacter.

[7]  Y. Kinoshita,et al.  Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis , 2001, Journal of gastroenterology and hepatology.

[8]  A. Berstad,et al.  Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease , 2001, American Journal of Gastroenterology.

[9]  D. Revicki,et al.  The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. , 2001, Archives of internal medicine.

[10]  Y. Kinoshita,et al.  Helicobacter pylori infection influences nocturnal gastric acid breakthrough , 2000, Alimentary pharmacology & therapeutics.

[11]  L. Lachman,et al.  Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration , 2000, American Journal of Gastroenterology.

[12]  Jansen,et al.  Standard‐dose lansoprazole is more effective than high‐dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis , 1999, Alimentary pharmacology & therapeutics.

[13]  A. Blum,et al.  Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification , 1999, Gut.

[14]  M. Samsom,et al.  The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine , 1999, Alimentary pharmacology & therapeutics.

[15]  J. Hüsler,et al.  Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hoursFigure 1 , 1999, American Journal of Gastroenterology.

[16]  D. Castell,et al.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors , 1998, American Journal of Gastroenterology.

[17]  N. Arebi,et al.  How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. , 1997, Gastroenterology.

[18]  R. Hunt,et al.  The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. , 1997, Clinical therapeutics.

[19]  G. Sachs.  Proton Pump Inhibitors and Acid‐Related Diseases , 1997, Pharmacotherapy.

[20]  J. Dent,et al.  Transient lower esophageal sphincter relaxation. , 1995, Gastroenterology.

[21]  G. Vantrappen,et al.  How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? , 1995, Digestive Diseases and Sciences.

[22]  F. Halter,et al.  Comparison of acid inhibition by either oral high‐dose ranitidine or omeprazole , 1994, Alimentary pharmacology & therapeutics.

[23]  R. Hunt,et al.  Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. , 1992, Gut.

[24]  駒澤 慶憲.  Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subject without Helicobacter pylori infection , 2003 .

[25]  P. Marquis,et al.  Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). , 1999, Scandinavian journal of gastroenterology. Supplement.

[26]  I. Wiklund,et al.  Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. , 1996, Scandinavian journal of gastroenterology. Supplement.

[27]  E. Dimenüs,et al.  Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. , 1993, Scandinavian journal of gastroenterology. Supplement.